Exploring the Impact of Airway Microbiome on Asthma Morbidity: A Focus on the “Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma—CURE” Project
Pulmonary Therapy · 2024-06 · 10 (2) · 171-182
DOI: 10.1007/s41030-024-00261-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pulmonary Therapy, online erschienen am 30.05.2024. Verfasst von Paraskevi Xepapadaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, 41, Fidippidou, 11527, Athens, Greece. vickyxepapadaki@gma…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HORIZON EUROPE Framework Programme.
Abstract (Originalsprache)
The asthma pandemic imposes a huge burden on patients and health systems in both developed and developing countries. Despite available treatments, symptom control is generally suboptimal, and hospitalizations and deaths remain at unacceptably high levels. A pivotal aspect of asthma that warrants further exploration is the influence of the respiratory microbiome and virome in modulating disease activity. A plethora of studies report that the respiratory microbiome is characteristically dysbiotic in asthma. In addition, our data suggest that dysbiosis is also observed on the respiratory virome, partly characterized by the reduced abundance of bacteriophages (phages). Even though phages can naturally infect and control their bacterial prey, phage therapy has been grossly neglected in the Western world, although more recently it is more widely used as a novel tool against bacterial infections. However, it has never been used for tackling microbiome dysbiosis in human non-communicable diseases. This review provides an up-to-date understanding of the microbiome and virome's role within the airways in relation to asthma morbidity. It also advances the rationale and hypothesis for the CURE project. Specifically, the CURE project suggests that managing the respiratory microbiome through phage therapy is viable and may result in restoring eubiosis within the asthmatic airway. This entails controlling immune dysregulation and the clinical manifestation of the disease. To accomplish this goal, it is crucial to predict the effects of introducing specific phage mixtures into the intricate ecology of the airways and devise suitable interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, 41, Fidippidou, 11527, Athens, Greece. vickyxepapadaki@gmail.com.
- Department of Genetics and Genome Biology, Centre for Phage Research, University of Leicester, Leicester, UK.
- 1st Department of Respiratory Medicine, Sotiria Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527, Athens, Greece.
- Department of Immunology and Allergy, Medical University, Lodz, Poland.
- Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, 41, Fidippidou, 11527, Athens, Greece.
Förderung
- HORIZON EUROPE Framework Programme
Zitieren
APA
Xepapadaki, P., Megremis, S., Rovina, N., Wardzyńska, A., Pasioti, M., Kritikou, M., Papadopoulos, N. G., & CURE Consortium (2024). Exploring the Impact of Airway Microbiome on Asthma Morbidity: A Focus on the “Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma—CURE” Project. Pulmonary Therapy, 10(2), 171-182. https://doi.org/10.1007/s41030-024-00261-3
Vancouver
Xepapadaki P, Megremis S, Rovina N, Wardzyńska A, Pasioti M, Kritikou M, et al. Exploring the Impact of Airway Microbiome on Asthma Morbidity: A Focus on the “Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma—CURE” Project. Pulmonary Therapy. 2024;10(2):171-182. doi:10.1007/s41030-024-00261-3
BibTeX
@article{Xepapadaki2024,
author = {Xepapadaki, Paraskevi and Megremis, Spyridon and Rovina, Nikoletta and Wardzyńska, Aleksandra and Pasioti, Maria and Kritikou, Maria and Papadopoulos, Nikolaos G and CURE Consortium, CURE Consortium},
title = {Exploring the Impact of Airway Microbiome on Asthma Morbidity: A Focus on the “Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma—CURE” Project},
journal = {Pulmonary Therapy},
year = {2024},
volume = {10},
number = {2},
pages = {171--182},
doi = {10.1007/s41030-024-00261-3}
}
EUVIMED